The Surgical Infection Society revised guidelines on the management of intra-abdominal infection

Background: Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline was released, the plan was to update the guideline every five years to ensure the timeliness and appropriateness of the recommendations. Methods: Based on the previous guidelines, the task force outlined a number of topics related to the treatment of patients with IAI and then developed key questions on these various topics. All questions were approached using general and specific literature searches, focusing on articles and other information published since 2008. These publications and additional materials published before 2008 were reviewed by the task force as a whole or by individual subgroups as to relevance to individual questions. Recommendations were developed by a process of iterative consensus, with all task force members voting to accept or reject each recommendation. Grading was based on the GRADE (Grades of Recommendation Assessment, Development, and Evaluation) system; the quality of the evidence was graded as high, moderate, or weak, and the strength of the recommendation was graded as strong or weak. Review of the document was performed by members of the SIS who were not on the task force. After responses were made to all critiques, the document was approved as an official guideline of the SIS by the Executive Council. Results: This guideline summarizes the current recommendations developed by the task force on the treatment of patients who have IAI. Evidence-based recommendations have been made regarding risk assessment in individual patients; source control; the timing, selection, and duration of antimicrobial therapy; and suggested approaches to patients who fail initial therapy. Additional recommendations related to the treatment of pediatric patients with IAI have been included. Summary: The current recommendations of the SIS regarding the treatment of patients with IAI are provided in this guideline

Oral Cancer Development in Patients with Leukoplakia – Clinicopathological Factors Affecting Outcome

Oral leukoplakia (OL) is the best-known potentially malignant disorder. The objective of the current study was to evaluate the clinicopathological factors predictive of outcome in a large cohort of patients with OL, and report our experience in the early detection of malignant events.A total of 320 patients with biopsy-proven OL were retrospectively reviewed from the study institution who had a mean follow-up of 5.1 years. Data on patient and lesion at initial diagnosis and patient underwent sequential biopsies were reviewed. Multiple biopsies indicates > = 3 times sequential biopsies. Oral cancer-free survival rate (OCFS) was determined by the Kaplan-Meier method and significant factors were identified by Cox regression analysis.<0.001), especially during the first 2–3 years of follow-up. Multivariate analysis revealed that the 4 factors including patient aged >60 years, lesion located at lateral/ventral tongue, non-homogenous lesion, high-grade dysplasia were independent significant indicators for OL malignant transformation. In addition, significant positive correlation between the multiple biopsies and these 4 factors and malignant outcome was established.Elderly patients with OL located at lateral/ventral tongue and who had non-homogenous lesion with high-grade dysplasia correlated much higher risk of transformation. This high-risk subpopulation was suggested to undergo sequential biopsies and histologic examination contributing to early detection of malignant event

A Naturally Occurring Inhibitory Agent from Hypericum sampsonii. with Activity Against Multidrug-Resistant Staphylococcus aureus .

Bioassay-directed fractionation employing a multidrug-resistant (MDR) strain of Staphylococcus aureus. resulted in the isolation of an antibacterial prenyl substituted xanthone derivative (1) named hyperixanthone A from the root of Hypericum sampsonii. Hance (Hyperiaceae). Compound 1 showed promising inhibitory activity against the norfloxacin-resistant S. aureus. strain SA-1199B at a minimum inhibitory concentration (MIC) of 2 μ g/mL (4.3 μ M), wheres the positive standard antibacterial drug norfloxacin showed an MIC of 32 μ g/mL (100 μ M). This strain overexpresses the NorA multidrug efflux transporter, the major characterized drug pump in Staphylococcus aureus.. The activity of this compound against an effluxing strain of S. aureus. is reported here for the first time. Compound 1, together with 1,7-dihydroxyxanthone (2) and 2-hydroxyxanthone (3), were obtained by silica gel column chromatography, and their structures were determined by means of extensive NMR and MS spectra